GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » PB Ratio

Medicenna Therapeutics (TSX:MDNA) PB Ratio : 7.28 (As of Apr. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-26), Medicenna Therapeutics's share price is C$1.95. Medicenna Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was C$0.27. Hence, Medicenna Therapeutics's PB Ratio of today is 7.28.

The historical rank and industry rank for Medicenna Therapeutics's PB Ratio or its related term are showing as below:

TSX:MDNA' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 7.32
Current: 6.12

During the past 9 years, Medicenna Therapeutics's highest PB Ratio was 7.32. The lowest was 0.00. And the median was 0.00.

TSX:MDNA's PB Ratio is ranked worse than
82.14% of 1310 companies
in the Biotechnology industry
Industry Median: 2.385 vs TSX:MDNA: 6.12

During the past 12 months, Medicenna Therapeutics's average Book Value Per Share Growth Rate was -43.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -18.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 40.80% per year.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Medicenna Therapeutics was 100.80% per year. The lowest was -64.70% per year. And the median was 11.50% per year.

Back to Basics: PB Ratio


Medicenna Therapeutics PB Ratio Historical Data

The historical data trend for Medicenna Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics PB Ratio Chart

Medicenna Therapeutics Annual Data
Trend Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
PB Ratio
Get a 7-Day Free Trial Premium Member Only 8.26 4.66 7.18 4.41 2.08

Medicenna Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.34 2.08 1.66 1.19 1.57

Competitive Comparison of Medicenna Therapeutics's PB Ratio

For the Biotechnology subindustry, Medicenna Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicenna Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's PB Ratio falls into.



Medicenna Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Medicenna Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1.95/0.268
=7.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Medicenna Therapeutics  (TSX:MDNA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Medicenna Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicenna Therapeutics (TSX:MDNA) Business Description

Traded in Other Exchanges
Address
2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Medicenna Therapeutics (TSX:MDNA) Headlines

No Headlines